CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
Bradly DP, Gattuso P, Pool M, Basu S, Liptay M, Bonomi P, Buckingham L. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.